Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Akebia Therapeutics Stock Forecast NASDAQ:AKBA
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-05-16 | 257.14% | HC Wainwright & Co. | $2.00 $1.25 | Maintains | Neutral |
| 2022-03-31 | 471.43% | Piper Sandler | $8.00 $2.00 | Downgrades | Overweight Neutral |
| 2022-03-31 | 471.43% | Mizuho | $6.00 $2.00 | Downgrades | Buy Neutral |
| 2022-03-31 | - | Needham | - | Downgrades | Buy Hold |
| 2022-03-31 | 471.43% | HC Wainwright & Co. | $10.00 $2.00 | Downgrades | Buy Neutral |
| 2021-11-11 | 2757.14% | HC Wainwright & Co. | $6.00 $10.00 | Maintains | Buy |
| 2021-03-08 | 2185.71% | Cantor Fitzgerald | $8.00 | Initiates Coverage On | Overweight |
| 2021-03-08 | 1614.29% | HC Wainwright & Co. | $9.00 $6.00 | Maintains | Buy |
| 2021-01-29 | - | JP Morgan | - | Downgrades | Neutral Underweight |
| 2020-10-26 | 2471.43% | HC Wainwright & Co. | $10.00 $9.00 | Maintains | Buy |
| 2020-09-04 | 2757.14% | HC Wainwright & Co. | $17.00 $10.00 | Maintains | Buy |
| 2020-09-04 | 1614.29% | BTIG | $26.00 $6.00 | Maintains | Buy |
| 2020-09-04 | 757.14% | Morgan Stanley | $12.00 $3.00 | Maintains | Equal-Weight |
| 2020-07-15 | 3328.57% | Morgan Stanley | $11.00 $12.00 | Maintains | Equal-Weight |
| 2020-05-06 | 5042.86% | JP Morgan | $13.00 $18.00 | Maintains | Overweight |
| 2020-05-06 | 3042.86% | Morgan Stanley | $9.00 $11.00 | Maintains | Equal-Weight |
| 2020-05-06 | 4757.14% | HC Wainwright & Co. | $16.00 $17.00 | Maintains | Buy |
| 2020-05-06 | 4757.14% | Mizuho | $15.00 $17.00 | Maintains | Buy |
| 2020-05-05 | 5042.86% | Needham | $15.00 $18.00 | Maintains | Buy |
| 2020-03-11 | 4185.71% | Mizuho | $16.00 $15.00 | Reiterates | Buy |
| 2020-02-20 | 3614.29% | JP Morgan | $10.00 $13.00 | Maintains | Overweight |
| 2019-11-18 | 4471.43% | HC Wainwright & Co. | $17.00 $16.00 | Maintains | Buy |
| 2019-08-06 | 4757.14% | HC Wainwright & Co. | $19.00 $17.00 | Maintains | Buy |
AKBA Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Due to the high volatility and the trend direction we are not able to give forecast range for this stock. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-23 | $-0.58 | $-0.0038 | $0.57 |
| 2022-05-24 | $-0.62 | $-0.0501 | $0.52 |
| 2022-05-25 | $-0.67 | $-0.0964 | $0.48 |
| 2022-05-26 | $-0.72 | $-0.14 | $0.43 |
| 2022-05-27 | $-0.76 | $-0.19 | $0.38 |
| 2022-05-31 | $-0.81 | $-0.24 | $0.34 |
| 2022-06-01 | $-0.85 | $-0.28 | $0.29 |
| 2022-06-02 | $-0.90 | $-0.33 | $0.24 |
| 2022-06-03 | $-0.95 | $-0.37 | $0.20 |
| 2022-06-06 | $-0.99 | $-0.42 | $0.15 |
| 2022-06-07 | $-1.04 | $-0.47 | $0.11 |
| 2022-06-08 | $-1.09 | $-0.51 | $0.0595 |
| 2022-06-09 | $-1.13 | $-0.56 | $0.0132 |
| 2022-06-10 | $-1.18 | $-0.61 | $-0.0331 |
| 2022-06-13 | $-1.22 | $-0.65 | $-0.0794 |
| 2022-06-14 | $-1.27 | $-0.70 | $-0.13 |
| 2022-06-15 | $-1.32 | $-0.74 | $-0.17 |
| 2022-06-16 | $-1.36 | $-0.79 | $-0.22 |
| 2022-06-17 | $-1.41 | $-0.84 | $-0.26 |
| 2022-06-21 | $-1.46 | $-0.88 | $-0.31 |
| 2022-06-22 | $-1.50 | $-0.93 | $-0.36 |
| 2022-06-23 | $-1.55 | $-0.98 | $-0.40 |
| 2022-06-24 | $-1.60 | $-1.02 | $-0.45 |
| 2022-06-27 | $-1.64 | $-1.07 | $-0.50 |
| 2022-06-28 | $-1.69 | $-1.11 | $-0.54 |
| 2022-06-29 | $-1.73 | $-1.16 | $-0.59 |
| 2022-06-30 | $-1.78 | $-1.21 | $-0.63 |
| 2022-07-01 | $-1.83 | $-1.25 | $-0.68 |
| 2022-07-05 | $-1.87 | $-1.30 | $-0.73 |
| 2022-07-06 | $-1.92 | $-1.35 | $-0.77 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
